Report: New Cholesterol Drugs Too Costly
/https://static.texastribune.org/media/images/nurse-phone001.jpg)
Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review, an outside nonprofit which monitors cost and care issues. The companies that make the new drugs question the nonprofit’s methodology and some pharmacies have been pressing for significant discounts. (Wall Street Journal)